Markets Earnings Screener Watchlist

Fundamentals and filings are sourced from SEC EDGAR. Market data, ownership and analyst consensus are sourced from Nasdaq. Written analysis is generated by metir from those sources and the linked reporting.

All information is provided for informational purposes only. It is not investment, financial, tax or legal advice, is not a recommendation to buy or sell any security, and is not intended for trading purposes. Data may be delayed or incomplete.

Gilead Sciences, Inc. Stock Price: Quote, Financials, Forecast & News (GILD)

Markets open

Gilead Sciences, Inc.

GILD · NASDAQ-GS

Overview Financials Earnings Holders Historical Data Analysis

$130.81-$4.503.33%

As of: Aug 5, 6:14 PM

Prev Close: $135.25
Market Cap: $162.41B
Open: —
Trailing P/E: —
Day Range: $137.80 - $129.60
52W Range: $157.29 - $108.46
Forward P/E: —
EPS: —
Volume: 6.65M
Dividend Yield: 2.43%

Notable Price Movement

Weekly movement commentary will appear here once it has been generated for this company.

Stories & Analysis

Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics

Zacks · 19h ago

Gilead Swings To Q2 Loss On Acquisition Charges

RTTNews · 21h ago

Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates

Zacks · 21h ago

After-Hours Earnings Report for August 4, 2026 : AMD, ANET, AMGN, GILD, BKNG, EMR, SU, EOG, ALAB, DVN, PRU, CPNG

NASDAQ.com · 1d ago

MRK Q2 Earnings & Sales Beat Estimates, '26 Sales View Raised

Zacks · 1d ago Ascentage Appoints Miyara As CBO And Ziegler As COO To Support Global Expansion

RTTNews · 2d ago Biotech Stocks Facing FDA Decision In August 2026

RTTNews · 5d ago Seeking Clues to Gilead (GILD) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics

Zacks · 6d ago

Symbol: GILD
Type: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
Country: North America
Exchange: NASDAQ-GS

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Analyst Consensus

Buy

24 analysts

$131

Current

—

Low

$162

Average

—

High

Average target implies +23.84% versus the current price.

Earnings History

BeatMissNo estimate

Peers

Abbott LaboratoriesABT · NYSE$104.66

0.76%

Novo Nordisk A/SNVO · NYSE$44.731.02%

Amgen Inc.AMGN · NASDAQ-GS$406.144.13%

AstraZeneca PLC Ordinary SharesAZN · NYSE$161.643.87%

Beta

—

Avg Volume

7.91M